MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results
PremiumCompany AnnouncementsMeiraGTx Holdings Reports Promising Parkinson’s Therapy Results
29d ago
MeiraGTx announces data from its study of AAV-GAD
Premium
The Fly
MeiraGTx announces data from its study of AAV-GAD
29d ago
MeiraGTx granted FDA orphan designation for treatment of Bardet-Biedl syndrome
Premium
The Fly
MeiraGTx granted FDA orphan designation for treatment of Bardet-Biedl syndrome
1M ago
MeiraGTx transferred with Buy rating at Chardan
PremiumThe FlyMeiraGTx transferred with Buy rating at Chardan
4M ago
MeiraGTx reports Q1 EPS (32c) vs. (62c) last year
Premium
The Fly
MeiraGTx reports Q1 EPS (32c) vs. (62c) last year
6M ago
MeiraGTx expects cash to fund requirements into 1Q26
Premium
The Fly
MeiraGTx expects cash to fund requirements into 1Q26
8M ago
MeiraGTx price target lowered to $18 from $19 at BofA
PremiumThe FlyMeiraGTx price target lowered to $18 from $19 at BofA
11M ago
MeiraGTx files $250M mixed securities shelf
Premium
The Fly
MeiraGTx files $250M mixed securities shelf
11M ago
MeiraGTx announces asset purchase agreement with Janssen for bota-vec
Premium
The Fly
MeiraGTx announces asset purchase agreement with Janssen for bota-vec
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100